TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin
- Author
- Vincent Racaniello
- Published
- Sat 18 Jun 2022
- Episode Link
- https://www.microbe.tv/twiv/twiv-910/
In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Tixagevimab-Cilgavimab for infection prevention (NEJM)
- Ivermectin for outpatient infection treatment (medRxiv)
- Symptom rebound after PAXLOVID treatment (IDSA)
- Bamlanivimab minimally impacts immune response to vaccination (Sci Transl Med)
- In-hospital morality among infected patients (IDSA)
- Casirvimab/Imdevimab & Remdesivir for infected B-cell depleted patients (IDSA)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Residual viral antigen in patients post infection (IDSA)
- Rheumatic symptoms following infection (IDSA)
- Contribute to FIMRC fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 910
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]
